Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.54 USD | +5.79% | +3.55% | +38.32% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.32% | 6.17B | |
+29.66% | 49.18B | |
+0.86% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.64% | 26.09B | |
-22.74% | 18.71B | |
+8.53% | 13.26B | |
+32.24% | 12.32B | |
-1.04% | 11.99B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating